A double blind, multicentre, placebo controlled trial of lornoxicam in patients with osteoarthritis of the hip and knee.

Berry, H; Bird, H. A.; Black, Cheryl; Blake, David R.; Freeman, Abigail M.; Golding, Douglas N.; Hamilton, Edith; Jayson, M. I. V.; Kidd, Bruce L.; Kohn, H

doi:10.1136/ard.51.2.238

Cited by 37 publications

(19 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lornoxicam effectively relieved the symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis (for review see [6]) [7,8]. Strong analgesic effects of lornoxicam were also observed after dental surgery, hysterectomy, lumbar disk surgery and in controlling lower back pain [9][10][11][12].…”

Section: Introductionmentioning

confidence: 99%

The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro

Berg

Fellier²,

Christoph³

et al. 1999

Inflamm. res.

106

View full text Add to dashboard Cite

Of the panel of NSAIDs tested, lornoxicam was found to be the most potent balanced inhibitor of human COX-1/-2. The equipotent COX-isoenzyme inhibition by lornoxicam is complemented by a marked inhibition of IL-6 production and of iNOS-derived NO formation. The in vitro activities described support the marked anti-inflammatory and analgesic activities of lornoxicam found in animal models as well as in clinical studies.

show abstract

Section: Introductionmentioning

confidence: 99%

The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro

Berg

Fellier²,

Christoph³

et al. 1999

Inflamm. res.

106

View full text Add to dashboard Cite

show abstract

“…Lornoxicam is a new compound combining the potency of the oxicams with a reduced risk of side effects. In comparison with other oxicams, lornoxicam has a relatively short elimination halflife (3 to 5 h [2]) and good gastrointestinal tolerability [3][4][5] which is an advantage in terms of less side effects than other oxicams. Like other NSAIDs, the anti-inflammatory/ analgesic activity of lornoxicam is related to the inhibitory action on prostaglandin synthesis, via inhibition of cyclooxygenase (COX) activity in the COX pathway of arachidonic acid metabolism [6].…”

Section: Introductionmentioning

confidence: 99%

“…Clinical trials have demonstrated the analgesic effect of lornoxicam in patients with acute pain (acute sciatica/lumbosciatica and low back pain [10]) or chronic inflammatory pain (osteoarthritis, rheumatoid arthritis [4,5]), for review see [1]. In animal studies, lornoxicam had anti-inflammatory (carrageenan oedema) and analgesic (writhing test) activity about 10 times greater than that of tenoxicam [2].…”

Section: Introductionmentioning

confidence: 99%

Dose-related anti-inflammatory/analgesic effects of lornoxicam: A spinal c-Fos protein study in the rat

Buritova¹,

Besson²

1998

Inflammation Research

View full text Add to dashboard Cite

show abstract

“…For instance, four weeks' treatment with lornoxicam (6 mg once daily, 4 mg twice daily, and 6 mg twice daily) and placebo was tested in patients with osteoarthritis of the hip or knee [25]. A dose related efficacy of lornoxicam was shown by pain relief scores, which were significantly better than placebo during treatment with lornoxicam 8 mg and 12 mg daily, the effect of 12 mg daily being significantly superior to that of 8 mg daily.…”

Section: Osteoarthritismentioning

confidence: 99%

Xefo® Rapid: A novel effective tool for pain treatment

Homdrum¹,

Likar

Nell³

2006

Eur Surg

View full text Add to dashboard Cite

Ergebnisse: Lornoxicam kann oral und parenteral appliziert werden, zeichnet sich durch einen raschen Wirkungsbeginn, eine kurze Halbwertszeit und geringe Nebenwirkungen aus. Pharmakokinetische und pharmakologische Aspekte werden in dem Artikel dargestellt.Schlussfolgerungen: Lornoxicam (Xefo ® und Xefo ® Rapid) stellt eine wertvolle Alternative zu Opiaten in der postoperativen Schmerztherapie dar.Schlüsselwörter: Lornoxicam, Chirurgie, Pharmakologie.Summary. Background: A multimodal approach to perioperative pain, including nonsteroidal anti-inflammatory drugs (NSAIDs) is recommended. Lornoxicam is an NSAID of the oxicam class.Methods: Review on Lornoxicam.Results: Lornoxicam is available in oral (standard and quick-release) and parenteral formulations. It is characterised by a relatively quick onset of action and a short elimination half-life. Several studies have shown the efficacy of lornoxicam in the perioperative setting. Lornoxicam was as effective as opioid analgesics in reducing postoperative pain and showed a better tolerability profile. Due to its opioid-sparing effect, lornoxicam might also be used in combination with opioid analgesics. In addition, it was comparable to other NSAIDs in treating musculoskeletal pain, like osteoarthritis and back pain. Safety and tolerability of lornoxicam show advantages when compared to other NSAIDs, with gastrointestinal disturbances being the most common adverse reactions. The report rate of adverse events was very low in the available studies, which could be a positive effect of the short half-life.Conclusions: Lornoxicam (Xefo ® and Xefo ® Rapid) is a valuable tool for relieving postoperative pain as an alternative to or adjuvant for opioid analgesics.

show abstract

A double blind, multicentre, placebo controlled trial of lornoxicam in patients with osteoarthritis of the hip and knee.

Cited by 37 publications

References 6 publications

The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro

The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro

Dose-related anti-inflammatory/analgesic effects of lornoxicam: A spinal c-Fos protein study in the rat

Xefo® Rapid: A novel effective tool for pain treatment

Contact Info

Product

Resources

About